索引超出了数组界限。
[1] Lee EJ, Lee AI. Thrombocytopenia[J]. Prim Care, 2016, 43(4):543-557.
[2] Meghrajani V, Sabharwal N, Namana V, et al. A case of hyperacute severe thrombocytopenia occurring less than 24 hours after intravenous tirofiban infusion[J]. Case Rep Hematol, 2018, 2018:4357981.
[3] Shenoy C, Harjai KJ. Thrombocytopenia following percutaneous coronary intervention[J]. J Interv Cardiol, 2011, 24(1):15-26.
[4] 汪云鑫, 苏乙花, 吴若霞. 经皮冠状动脉介入术后氯吡格雷相关血小板减少1例[J]. 心肺血管病杂志, 2018, 37(12):1129-1130.
[5] Prince M, Wenham T. Heparin-induced thrombocytopaenia[J]. Postgrad Med J, 2018, 94(1114):453-457.
[6] Lovecchio F. Heparin-induced thrombocytopenia[J]. Clin Toxicol(Phila), 2014, 52(6):579-583.
[7] 刘爱国. 肝素诱导血小板减少症的诊治进展[J]. 中国小儿血液与肿瘤杂志, 2019, 24(4):169-172.
[8] Frazer CA. Heparin-induced thrombocytopenia[J]. J Infus Nurs, 2017, 40(2):98-100.
[9] Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized efficacy study of tirofiban for outcomes and Restenosis[J]. Circulation, 1997, 96(5):1445-1453.
[10] Said SM, Hahn J, Schleyer E, et al. Glycoprotein Ⅱb/Ⅲa inhibitor-induced thrombocytopenia: diagnosis and treatment[J]. Clin Res Cardiol, 2007, 96(2):61-69.
[11] Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting[J]. Circulation, 2004, 109(18):2203-2206.
[12] Hashemzadeh M, Furukawa M, Goldsberry S, et al. Chemical structures and mode of action of intravenous glycoprotein Ⅱb/Ⅲa receptor blockers: a review[J]. Exp Clin Cardiol, 2008, 13(4):192-197.
[13] Joly BS, Coppo P, Veyradier A. Pediatric thrombotic thrombocytopenic purpura[J]. Eur J Haematol, 2018, 101(4):425-434.
[14] 张明, 刘德敏, 崔炜. 肝素诱导的血小板减少症治疗的研究进展[J]. 心血管病学进展, 2019, 40(9):1219-1223.